Morphosys AG (MORG.DE)
|Market Cap (Mil.):||€1,942.34|
|Shares Outstanding (Mil.):||26.37|
July 28 - Shares in Morphosys AG rise 2.6 percent at open after Q2 results
July 28 - Morphosys AG : * Says H1 revenues from continuing operations were EUR 30.5 million (H1 2013:
FRANKFURT, June 12 - Morphosys AG : * Says enters strategic immuno-oncology collaboration * Says Morphosys and Merck Serono enter strategic immuno-oncology collaboration
FRANKFURT, May 20 - Morphosys AG : * Says mor208 program to receive orphan drug designation from FDA and ema for
FRANKFURT, April 29 - Morphosys AG : * Shares rise 3.1 percent in early trade after results
FRANKFURT, April 29 - Morphosys AG : * Says group revenues decreased by 6% to EUR 15.9 million compared to the same
FRANKFURT, March 3 - Morphosys AG : * Says to repurchase up to 111,000 of its own shares over the stock market * Says to repurchase shares during the time period from 4 March 2014 to 28
FRANKFURT, Feb 28 - Morphosys AG : * Says group revenues from continuing operations amounted to EUR 78.0 million * Says earnings before interest and taxes (EBIT) reached EUR 9.9 million * Says group revenues will decrease in 2014 * Sees consolidated net profit amounted to EUR 13.3 million * Says sees revenues 58-63 million EUR, an EBIT in the range of EUR -11 to EUR
Earnings vs. Estimates
Analyst Research Reports
Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.